With RFK Jr. in Charge, Supplement Makers See Chance To Cash In

Last fall, before being named the senior U.S. health official, Robert F. Kennedy Jr. said the Trump administration would liberate Americans from the FDA’s “aggressive suppression” of vitamins, dietary supplements, and other substances — ending the federal agency’s “war on public health,” as he put it. In fact, the FDA can’t even require that supplements…

Read More

What is Project IDEATE?

How best can you design an outcomes based agreement (OBA)? What are the key factors to consider? Project IDEATE is a “cross-disciplinary collaboration between National Health Service (NHS) Wales, industry and academia” with the aim to develop and refine OBA models. What were the key factors IDEATE considered for an OBA? Feasibility: Identify parameters to…

Read More

Lynda Brown-Ganzert, RxPx

Lynda Brown-Ganzert is CEO of RxPx. The company is the 2022 merger of the company she founded, Curatio, which was a support system for rare disease patients, with RxMx, a complementary service that helped clinicians manage patients on treatment or clinical trials. Lynda says that somehow I inspired the merger! (Although I don’t remember it,…

Read More

Montana’s Medicaid Expansion Conundrum

HELENA, Mont. — Despite concerns about what Congress and the Trump administration might have planned for Medicaid, Montana’s Republican-led legislature and GOP governor appear ready to keep the state’s Medicaid expansion program in place beyond its scheduled end date this summer. State lawmakers don’t have the luxury of waiting until the federal picture sharpens. They…

Read More

Watch: What Is Medicaid, Again?

Republicans in Congress have suggested big cuts to Medicaid. But what exactly is it? Medicaid, the state-federal health insurance program for people with low incomes or disabilities, is integral to the U.S. health care system. It keeps hospitals and other providers afloat, provides a key source of federal funds to states, and helps provide health…

Read More

Trump Froze Out Project 2025 in His Campaign. Now Its Blueprint Is His Health Care Playbook.

Few voters likely expected President Donald Trump in the first weeks of his administration to slash billions of dollars from the nation’s premier federal cancer research agency. But funding cuts to the National Institutes of Health were presaged in Project 2025’s “Mandate for Leadership,” a conservative plan for governing that Trump said he knew nothing…

Read More

Can the NIH replace all private sector clinical R&D?

A paper by Proudman et al. (2024) finds that doing so would be extremely expensive. Including all preclinical, clinical and post-approval R&D activities, total annual costs to maintain the average lifecycle level of 49.4 approved drugs across all disease areas during the 2018–22 period was estimated to be $139.6 billion. Including only pre-launch costs, total…

Read More